Invasive fungal infections in the intensive care unit

Seminars in Respiratory and Critical Care Medicine

Volumn 31, Issue 1, 2010, Pages 79-86

  Vazquez, Jose A ^a,b  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungals; Candidiasis; ICU; Outcomes; Systemic fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA; CANDIDA ENDOPHTHALMITIS; CANDIDEMIA; CANDIDIASIS; CLINICAL FEATURE; FLUORESCENCE IN SITU HYBRIDIZATION; FUNGUS CULTURE; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS; CRITICAL ILLNESS; DRUG INTERACTIONS; EARLY DIAGNOSIS; HUMANS; INTENSIVE CARE UNITS; MYCOSES; SEVERITY OF ILLNESS INDEX;

EID: 76749097678     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1246289     Document Type: Review

References (38)

1. Martin G S., Mannino D M., Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348 1546-1554
2. Vazquez J A., Sobel J D. Candidiasis In: Dismukes WE, Pappas PG, Sobel JD Clinical Mycology. London Oxford University Press 2003 143-187
3. Pfaller M A., Diekema D J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 133-163
4. Pappas P G. Invasive candidiasis. Infect Dis Clin North Am 2006 20 485-506
5. Horn D L., Neofytos D, Anaissie E J. et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009 48 1695-1703
6. Pappas P G., Rex J H., Lee J et al, NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003 37 634-643
7. Morgan J. Global trends in candidemia: review of reports from 19952005. Curr Infect Dis Rep 2005 7 429-439
8. Colombo A L., Nucci M, Park B J. et al, Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006 44 2816-2823
9. Eiland E H., Hassoun A, English T. Points of concern related to the micafungin versus caspofungin trial. Clin Infect Dis 2008 46 640-641, author reply 641
10. Yang Y L. Virulence factors of Candida species. J Microbiol Immunol Infect 2003 36 223-228
11. Wey S B., Mori M, Pfaller M A., Woolson R F., Wenzel R P. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988 148 2642-2645
12. Menzin J M., Meyers J L., Friedman M et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009 66 1711-1717
13. Rentz A M., Halpern M T., Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998 27 781-788
14. Shah C P., McKey J, Spirn M J., Maguire J. Ocular candidiasis: a review. Br J Ophthalmol 2008 92 466-468
15. Morrell M, Fraser V J., Kollef M H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 49 3640-3645
16. Alexander B D., Pfaller M A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006 43 S15-S27
17. Shepard J R., Addison R M., Alexander B D. et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008 46 50-55
18. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004 39 199-205 (Pubitemid 38971490)
19. Pappas P G., Kauffman C A., Andes D et al, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 48 503-535
20. Kauffman C A. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006 9 483-488
21. Sable C A., Strohmaier K M., Chodakewitz J A. Advances in antifungal therapy. Annu Rev Med 2008 59 361-379
22. Chandrasekar P H., Sobel J D. Micafungin: a new echinocandin. Clin Infect Dis 2006 42 1171-1178
23. Sobel J D., Revankar S G. Echinocandinsfirst-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007 356 2525-2526
24. Kuse E R., Chetchotisakd P, da Cunha C A. et al, Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 1519-1527
25. Reboli A C., Rotstein C, Pappas P G. et al, Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 2472-2482
26. Cornely O A., Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007 60 363-369
27. Kullberg B J., Sobel J D., Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 1435-1442
28. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999 28 1071-1079
29. Khan F A., Slain D, Khakoo R A. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007 27 1711-1721
30. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006 57 384-410
31. Labelle A J., Micek S T., Roubinian N, Kollef M H. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008 36 2967-2972
32. Husain S, Paterson D L., Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006 6 3008-3016 (Pubitemid 44777932)
33. Ullmann A J., Cornely O A. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006 19 571-576
34. van Burik J A., Ratanatharathorn V, Stepan D E. et al, National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 39 1407-1416
35. Leleu G, Aegerter P, Guidet B, Collge des Utilisateurs de Base de Donnes en Ranimation. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002 17 168-175
36. Garey K W., Rege M, Pai M P. et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006 43 25-31
37. Meersseman W, Vandecasteele S J., Wilmer A, Verbeken E, Peetermans W E., Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004 170 621-625
38. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007 45 205-216